ArticleToxics2025
Toxicological Assessment of Ketamine in Juvenile Zebrafish (
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of a modified triple-combination anesthesia using dexmedetomidine in mice.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study investigates the toxic effects of ketamine on juvenile zebrafish, driven by increasing concerns over ketamine's prevalence and its potential neurotoxic effects that may disrupt behavior and metabolism. Employing a high-throughput behavior tracking system, the research analyzed the locomotor activity of 6-day post-fertilization (6 dpf) zebrafish exposed to various concentrations of ketamine. The integration of behavioral analysis with metabolic profiling was a notable innovation, as it establishes a comprehensive understanding of ketamine's effects on both acute behavioral inhibition and metabolic responses. The findings reveal that ketamine exposure significantly inhibits locomotor activity in juvenile zebrafish, with these effects becoming more pronounced at higher concentrations. Additionally, the detection of normethketamine, the primary metabolite of ketamine, using UPLC-LTQ/Orbitrap HRMS, confirms the zebrafish's ability to metabolize the drug. This underscores the utility of zebrafish as a model organism for studying the impact of ketamine on behavior and metabolism, providing valuable insights that may extend to other vertebrates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.